Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
Xoma (XOMA) Stock Price & Analysis
352 Followers
XOMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.48 - $27.00
Previous Close$25.51
Volume7.23K
Average Volume (3M)16.10K
Market Cap
$296.90M
Enterprise Value$263.21M
Total Cash (Recent Filing)$33.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-6.5
Beta0.19
Next Earnings
Aug 06, 2024EPS Estimate
-$0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.92
Shares Outstanding11,638,553
10 Day Avg. Volume8,891
30 Day Avg. Volume16,096
Standard Deviation0.18
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.42
Price to Sales (P/S)71.54
Price to Cash Flow (P/CF)-19.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue69.73
Enterprise Value/Gross Profit63.42
Enterprise Value/Ebitda-11.57
Forecast
1Y Price Target
$58.00Price Target Upside127.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Xoma News
Bulls Say, Bears Say
Bulls Say
Market OpportunityXOMA's partner, Day One, announced FDA accelerated approval of tovorafenib (OJEMDA), enhancing the company's growth prospects.
Revenue GrowthAnticipated royalty revenue from Xaciato, Ovaprene, and Sildenafil Cream contributes to future earnings projections.
Strategic AcquisitionsAnalyst increases DCF-based price target to $42 to include recently acquired royalty assets.
Bears Say
Financial ObligationsXOMA may face increased financial obligations to Daré if earnings surpass specific benchmarks, potentially reducing royalty rates on other assets.
Financial PerformanceRecent financial results have been adversely affected by impairment charges and the costs associated with arbitration.
Revenue ForecastingAnalyst concerns suggest that the current consensus sales projections fueling revenue expectations might be too ambitious.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $13.48 and its highest was $27.00 in the past 12 months.
What is Xoma Corp’s market cap?
Currently, no data Available
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Aug 06, 2024 which is in 80 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on May 09, 2024. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.71 by -$0.15.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -$0.43.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 11,638,553 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.71. Following the earnings report the stock price went down -2.107%.
Which hedge fund is a major shareholder of Xoma Corp?
Among the largest hedge funds holding Xoma Corp’s share is Woodline Partners LP. It holds Xoma Corp’s shares valued at 2M.
---
Xoma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$58.00 (127.36% Upside)
$58.00 (127.36% Upside)
Hedge Fund Trend
Increased
By 21.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.26%
12-Months-Change
Fundamentals
Return on Equity
-40.24%
Trailing 12-Months
Asset Growth
64.16%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
---
XOMA Stock 12 Month Forecast
Average Price Target
$58.00
▲(127.36% Upside)
Technical Analysis
Best Analysts Covering XOMA
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+31.27%
reiterated a buy rating 18 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +31.27% per trade.
---